Silence Therapeutics (SLN) Share Price, News & Analysis

Company Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 535 to 535
• 52-Week Range: N/A
• Volume: 913,528 shs
• Average Volume: 80,100 shs
• Market Capitalization: £480.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SLN Stock Analysis - Frequently Asked Questions

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) announced its quarterly earnings results on Monday, September, 14th. The company reported ($13.70) earnings per share for the quarter, beating analysts' consensus estimates of ($21.70) by $8.00.

How do I buy shares of Silence Therapeutics?

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY) and Anchiano Therapeutics (ANCN).

Company Calendar

• Last Earnings: 9/14/2020
• Today: 7/26/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:SLN
• CIK: N/A
• Web: www.silence-therapeutics.com
• Phone: +44-20-34576900
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.80
• Current Ratio: 4.52
• Quick Ratio: 4.36

Sales & Book Value

• Annual Sales: £11.35 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 6.34
• Book Value: GBX 18.20 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 89,785,000
• Free Float: N/A
• Market Cap: £480.35 million
• Optionable: Not Optionable
• Beta: N/A